PharmTech Weekly News Roundup – Week of December 8, 2025

In this PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week.

Collectively, the week’s coverage discusses the pharmaceutical industry’s recent developments and current regulatory landscape. Read on for recaps of each story we’ve covered.

How are current trends increasing HPAPI development complexity?

The highly potent active pharmaceutical ingredient (HPAPI) market is rapidly expanding, fueled by the industry's focus on oncology, precision medicine, and advanced delivery platforms such as antibody-drug conjugates. This increased complexity and potency demand advanced strategies, including flow chemistry, continuous manufacturing, and strict containment capabilities, while meeting rising environmental, safety, and governance expectations.

What role will automation and AI play in small-molecule drug manufacturing?

Automation is a strategic imperative that provides speed, consistency, quality, and helps address workforce shortages in small-molecule drug manufacturing. The increased role of artificial intelligence (AI) and machine learning is expected to drive optimization through predictive maintenance and real-time adjustments, supporting the long-term vision of a self-regulating, fully digital plant.

What formulation innovations are helping overcome limitations of injectable biologics?

R&D efforts are intensely focused on developing non-parenteral routes for biologics, including next-generation oral macrocycle drugs (nCycles) designed for better oral bioavailability. Other innovations include smart capsules that use mechanical or electronic components to achieve site-specific release in the stomach or intestine.

How will the EU's new pharmaceutical policy framework impact market exclusivity?

The European Union (EU) reform establishes a regulatory data and market protection period of eight years, capped at 11 years combined protection under the agreement. Additional protection is granted for medicines addressing unmet needs, developing new therapeutic indications, or meeting specific clinical trial conditions.

How is patient-centricity advancing discovery of new cancer therapeutics?

A new joint venture between the Wilmot Cancer Institute and Indivumed is accelerating the development of novel cancer therapeutics, initially focusing on advanced solid cancers. This approach uses AI-powered data analytics to identify targets and develop primary tumor models for testing novel compounds, aiming to improve patient adherence and outcomes.

Which process innovations are leading the way in optimizing manufacturing efficiency?

Efficiency is being optimized through the integration of sustainability, continuous processes, and modular equipment platforms. Innovations like continuous direct compression allow for rapid control and waste elimination, while advanced algorithms enable real-time optimization and preventive diagnostics.

What are the key applications of Raman spectroscopy in drug manufacturing and quality control?

Raman spectroscopy provides a rapid, non-destructive method valuable for quality control by characterizing the polymorphic phases of active ingredients in raw powders and final tablet formulations. This technique is also a critical tool against counterfeit drugs because it provides a unique molecular fingerprint and can analyze materials through packaging.